May 4, 2023 7:09pm
What a difference a session makes
Pre-Open Indications: 4 Hit and 1 Miss
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about - truth!
Subscription is coming, it is not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
Skim if you can trim, buy if it will fly and sell if compelled!
If I have learned one thing as a former research analyst in a venture and public fund, operating executive, adjunct (MBA) business school professor now a journalist; it is that your life and your portfolio are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed UP +55 points (+0.16%), the S&P closed UP +9.75 points (+0.24%) while the Nasdaq closed UP +34 points (+0.26%)
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies.
Indexes popped after the Fed pushing through its 10th rate hike.
Thursday, another rough session for regional bank stocks, with shares of several lender poised to suffer large drops.
The CBOE Volatility Index, or VIX, ticked higher again on Thursday after climbing 5.5% a day earlier.
The indexes are also tracking for a week of losses — the worst performance for all three since March 10; the S&P 500 is off 2.6%, the Nasdaq is off 2.1% while the Dow is down 2.8%.
Economic Data Docket: Jobless claims totaled 242,000 for the week ended April 29, higher than the 236,000 estimate from Dow Jones. Worker productivity in the first quarter declined 2.7% against the estimate for a 1.9% drop, while unit labor costs, an inflation gauge, accelerated 6.3% in Q1, higher than the 5.5% expectation.
· The trade deficit declined to $64.2 billion, but that was higher than the $63.1 billion estimate.
Thursday (5/4) … RegMed Investors’ (RMi) pre-open: “sustainability. The key to the sector’s share pricing during earnings loaded week.” … https://www.regmedinvestors.com/articles/12944
Pre-Open Indications: 4 Hit < Beam Therapeutics (BEAM +$1.63), CRISPR Therapeutics (CRSP +$3.93), Intellia Therapeutics (NTLA +$5.07), Prime Medicine (PRME +$0.74)> and 1 Miss < Sage Therapeutics (SAGE +$0.65)
RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened – differences …
- Thursday’s advance/decline line opened negative at 15 up/ 18 down and 2 flats, flipped positive with 26 up/ 8 down and 1 flat at the mid-day, ending with a positive close of 29/6 and 0 flat
Key Metrics:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
Thursday, the IBB was down- 0.29% and the XBI was up +0.93%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Thursday was up +1.75 points or +9.54% at 20.09
Closing Down (6 of 6):
- Regenxbio (RGNX -$0.32 after Wednesday’s +$0.74, Tuesday’s -$0.61 and Monday’s +$0.74),
- Fate Therapeutics (FATE -$0.15,
- Biostage (OTCQB: BSTG -$0.05),
- Compass Therapeutics (CMPX -$0.04),
- Precigen (PGEN -$0.03),
- Avrobio (AVRO -$0.0093)
Closing Up (10 of 26):
- Alnylam Pharmaceuticals (ALNY +$5.89),
- Intellia Therapeutics (NTLA +$5.07 after Wednesday’s +$1.58, Tuesday’s -$0.74 and Monday’s -$0.01)
- CRISPR Therapeutics (CRSP +$3.93 after Wednesday’s +$1.14 and Tuesday’s -$1.03),
- Ultragenyx (RARE +$2.48 after Wednesday’s +$0.82, Tuesday’s -$1.52 and Monday’s +$0.36),
- Beam Therapeutics (BEAM +$1.63 after Wednesday’s +$1.48),
- Ionis Pharmaceuticals (IONS +$1.25 after Wednesday’s -$0.79),
- Prime Medicine (PRME +$0.74),
- Sage Therapeutics (SAGE +$0.65 after Wednesday’s +$1.91, Tuesday’s -$3.09 and Monday’s -$0.43),
- Vericel (VCEL +$0.54 after Wednesday’s +$0.79, Tuesday’s -$0.89 and Monday’s +$0.71),
- uniQure NV (QURE +$0.42),
Q2/23 – May
- Thursday closed positive with 29 incliners, 6 decliners and 0 flat
The BOTTOM LINE: I try to keep it simple … and short!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
I MAINTAIN my recommendation, it’s Thursday after my Monday night’s post, “Skim if you can trim, buy if it will fly and sell if compelled!”
Have you asked yourself, do you know why you own certain equity? What’s been communicated re a company’s status at any given time to shareholders other than quarterly reports or a once-upon-a-time press release!
There are clear winners — and losers — at the start of May.
The top three performing are:
· Thursday - Alnylam Pharmaceuticals (ALNY), Intellia Therapeutics (NTLA) – again and CRISPR Therapeutics (CRSP)
· Wednesday - Sage Therapeutics (SAGE), Intellia Therapeutics (NTLA) and MiMedx (MDXG)
· Tuesday – Mesoblast (MESO), uniQure NV (QURE) and Brainstorm Cell Therapeutics (BCLI)
· Monday’s: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and Regenxbio (RGNX).
While The worst three (3):
· Thursday – Regenxbio (RGNX), Fate Therapeutics (FATE) and Biostage (OTCQB: BSTG)
· Wednesday – Ionis Pharmaceuticals (IONS), bluebird bio (BLUE) and Sangamo Therapeutics (SGMO)
· Tuesday - Sage Therapeutics (SAGE) – again, Alnylam Pharmaceuticals (ALNY) and Ultragenyx (RARE)
· Monday’s: Sage Therapeutics (SAGE), Chinook Therapeutics (KDNY). Avrobio (AVRO),
Percentage moves:
· Upside: +0.18% to +13.14% (29)
· Downside: -0.83% to -2.44% (6)
Earnings:
RegMed Investors (RMi) Research Note: Q1/23 earnings reporting dates, net losses, cash positions and runway outcomes … https://www.regmedinvestors.com/articles/12923 - added 4 today
WHY (?) do I keep posting, so investors can get a daily update of the sector's share pricing and some individual companies TRUTHS while electronic trading chews on our portfolio edges.
I am definitely considered a contrarian depending on the session – one has to be a watcher of the ups and downs as well as measurer of sentiment. I am also a NO trust investor but, a validate and verify journalist/analyst.
The NO spin zone! U.S. public shareholders deserve accountability …
De-Listing Update:
Avrobio (AVRO) – Thursday closed down -$0.0093 to $0.655 after Wednesday closed up +$0.01 to $0.66 after Tuesday’s Tuesday closed down-$0.168 to $0.65 after Monday closed down -$0.01596 to $0.83 after CEO Geoff MacKay resigned; still under Nasdaq minimum rule of $1.00; after twenty-three (23) sessions
· Will AVRO do a reverse split to up-end delisting to “SCREW” shareholders yet, AGAIN?
Verastem Oncology (VSTM) closed basically FLAT (+$0.0061) after Wednesday’s +$0.005 to $0.44 on Wednesday after Tuesday’s -$0.0070 after Monday’s -$0.075; two hundredth (200) sessions under the Nasdaq $1.00 minimum pricing
Biostage (OTCQB: BSTG) …
· Thursday closed down -$0.05 with 650 shares traded after Wednesday closed FLAT with 26 shares traded after Tuesday closed FLAT with 0 shares traded Monday closed FLAT with 0 shares traded after Friday closed FLAT with 0 shares traded, Thursday closed flat with 0 shares traded and last Wednesday closed flat with 27 shares <3-month average =1,588 shares>
· Question: Review the number of shares traded … is OTCQB: BSTG a Ponzi scheme (with their pump/promote buy and sell agenda) as shares are bought to replace those sold?
My question that resounds, that should be asked is how many companies are at the end of sentiments … leash?
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
